CRF receptor antagonists and methods relating thereto
AssigneeNeurocrine Biosciences, Inc.
InventorsMustapha Haddach, John Patrick Williams, Dragan Marinkovic, Jane Han Bu
Life of this patent
Estimating the term…
Abstract
CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals, such as stroke. The CRF receptor antagonists of this invention have the following structure: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein m, R, R1, R2, X, Y, A, B and C are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same
Claims22
A compound having the following structure:
- or a stereoisomer, prodrug or pharmaceutically acceptable salt thereof,
- wherein:
- X is nitrogen or CR3;
- Y is O or S(O)0-2;
- “- - - ” represents an option double bond;
- A and C are the same or different and independently nitrogen, carbon or CH;
- B is nitrogen or CR4;
- with the provisos that at least one of A, B or C is nitrogen, A, B and C are not all nitrogen, and either A—B or B—C is a double bond;
- R is an optional substituent which, at each occurrence, is independently alkyl, substituted alkyl, aryl, arylalkyl, alkylidenyl, heterocycle, heterocyclealkyl, alkoxy or —CO(alkoxy), wherein m is 0, 1, 2 or 3 and represents the number of R substituents;
- R1 is alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl;
- R2 is hydrogen, alkyl, alkoxy or thioalkyl or haloalkyl;
- R3 is hydrogen, alkyl, halogen or haloalkyl;
- and
- R4 is hydrogen, halogen, alkyl, alkoxy, thioalkyl or haloalkyl.
Dependencies are inferred from the claim text.